New knowledge of chondrocalcinosis

PAUL DIEPPE

From the Department of Medicine, University of Bristol

There are three varieties of cartilage—hyaline, elastic, and fibrocartilage. Hyaline cartilage is the precursor of bone. In the adult it is mainly found at bone ends, forming the load-bearing surface of synovial joints. Extra-articular fibrocartilages such as those of the trachea and ribs often calcify with advancing age. Articular cartilage, however, usually remains free from mineral deposits. The term 'chondrocalcinosis' may be defined as a pathological state characterised by the precipitation of insoluble calcium salts in articular and periarticular cartilage.

The presence of chondrocalcinosis can be proved only by crystallographic examination. Its presence may be inferred by radiological examination or the discovery of crystals in synovial fluid. In addition, articular chondrocalcinosis is sometimes accompanied by arthritis. There are therefore three separate phenomena associated with chondrocalcinosis—radiological changes, crystals in synovial fluid, and arthritis. These may occur separately or in any combination (Fig. 1).

The term 'chondrocalcinosis' was often used loosely in reference to radiological signs, the presence of pyrophosphate crystals in joints, or a characteristic form of arthritis. Recent work has highlighted the fact that many different crystals may be precipitated in cartilage and has led to a questioning of the causal relationship between crystals and arthritis. Further work would be aided by the use of a disciplined nomenclature—referring, for example, to articular pyrophosphate chondrocalcinosis—with a descriptive account of the associated features.

Calcium salts positively identified in human articular cartilage are: (1) calcium pyrophosphate dihydrate, Ca$_2$P$_2$O$_7$.2H$_2$O (pyrophosphate, CPPD); (2) hydroxyapatite, Ca$_{10}$(PO$_4$)$_6$(OH)$_2$ (hydroxyapatite, apatite, HA); and (3) dicalcium phosphate dihydrate, CaHPO$_4$.2H$_2$O (brushite, calcium phosphate dihydrate, DCPD).

Chondrocalcinosis may be classified according to (1) the nature of the deposit (pyrophosphate, hydroxyapatite, Brushite, or mixtures); (2) the type (familial, metabolic, sporadic, age associated); and (3) the metabolic associations: (a) hydroxyapatite (chronic renal disease); (b) pyrophosphate (hyperparathyroidism, haemachromatosis, hypothyroidism, hypophosphataxia, hypomagnesaemia, gout(?), diabetes mellitus (?), Wilson's disease (?), ochronosis (?)).

Historical perspective

Intra-articular calcification has been recognised for at least a century. It was mentioned by Garrod (1876) and by Adams (1872). With the advent of joint radiography there were a number of reports of calcification of knee menisci (Pearson and Davin, 1921). Wolke (1935) described five cases from 2569 knee radiographs. Žiťňan and Sifaj (1957) described 12 cases, and they later identified familial cases with polyarticular lesions and an associated arthritis (Žiťňan and Sifaj, 1976).

While Žiťňan and Sifaj surveyed joint radiographs Hollander and McCarty (1961) examined joint fluid by polarised light microscopy and discovered urate crystals in gout. McCarty et al. (1962) also noticed a different type of crystal in some patients with acute arthritis. They were identified by x-ray diffraction as calcium pyrophosphate dihydrate (CPPD) (Kohn et al., 1962).

Chondrocalcinosis has since been studied in various countries. Analysis of patients with radiological chondrocalcinosis by Currey (1966) and of those with pyrophosphate (PP) crystals in synovial fluid (Bjelle and Sundin, 1974) led to findings similar to those of Žiťňan and Sifaj and of McCarty, who has now reported on over 300 cases (McCarty, 1976). A pattern emerges of patients with linear calcification of hyaline cartilage identified on x-ray examination, PP crystals in synovial fluid, and an arthritis that is either acute oligo- or mono-articular ('pseudogout') or chronic destructive, similar to osteoarthritis ('chronic PP arthropathy'). Thus chondrocalcinosis becomes synonymous with PP deposition and its characteristic arthritis.

New crystals

McCarty and Gatter (1963) described the presence of dicalcium phosphate dihydrate in human fibro-
New knowledge of chondrocalcinosis

![Diagram of chondrocalcinosis]

**Fig. 1 Clinical association of chondrocalcinosis.**

cartilage and, later, the pathological findings in 215 cadaver knee menisci (McCarty et al., 1966). Three salts were identified: calcium pyrophosphate dihydrate (CPPD) (3.2%), dicalcium phosphate dihydrate (DCPD) (2.3%), and hydroxyapatite (HA) (1.4%). Vascular calcification in the outer one-third was also common (hydroxyapatite). Small unidentified deposits were seen in some specimens. No comprehensive study has been made on articular hyaline cartilage. Recently Ali (1977) has identified minute deposits of HA in osteoarthrotic hyaline cartilage, and Doyle et al. (1978) have made similar observations. Fibrocartilage seems to be peculiarly susceptible to PP deposits but hyaline cartilage may be more readily mineralized with HA.

Both DCPD and HA have recently been described in the synovial fluid and tissues of patients with arthritis. Moskowitz et al. (1971), Faure et al. (1977), and Utsinger (1977) have described DCPD-related arthritis, and Dieppe et al. (1976) and Schumacher et al. (1976) HA-related arthropathy. Combinations of these different salts also occur. Moskowitz et al. (1971) identified a mixture of PP and DCPD, and mixtures of PP and HA have been found in the same joint by Okazaki et al. (1976) and Dieppe et al. (1978).

Sophisticated techniques are needed to identify the calcified deposits. Diffraction patterns provide precise crystal analysis, and both PP and DCPD have been identified in this way. HA crystals are usually too small for single crystal diffraction but powder patterns have been obtained. Other indirect ways of identifying these substances include infrared spectroscopy and analytical electron microscopy (Dieppe et al. 1977). Many workers have used electron microscopy with attached x-ray energy spectroscopy to calculate the ratio of calcium and phosphorus in different crystals compared with known standards. This technique, however, cannot differentiate PP from DCPD (Crocker et al., 1977; Nuki et al., 1978). Polarising microscopy is another indirect technique, ideal for differentiating gout from pseudogout. But small HA crystals cannot be seen by light microscopy, and many different salts may form the positively birefringent crystals usually assumed to be PP (Gatter, 1977).

Complex analytical techniques and tissue processing may alter the mineral content from that present in vivo. More crystallography studies are therefore required before conclusions can be reached about the incidence and nature of the different deposits of chondrocalcinosis. A scheme combining several different analytical techniques is shown in Fig. 2.

**Site of deposits**

Intra-articular calcification was always thought to comprise PP and periartricular mineral deposits of HA (McCarty and Gatter, 1966; Pinal and Short, 1966). In neither case is this always so.

Calcium salts of PP form monoclinic and triclinic crystals. The latter predominate. They are deposited preferentially in fibrocartilage. The commonest site is the knee meniscus, followed by the symphysis pubis, wrist, and intervertebral discs. Shoulders, elbows, hips, metacarpophalangeal, and other joints may also be affected. Linear calcification of tendons is not uncommon. A recent study reported an incidence of 13.5%, the commonest sites being the tendon achilles, plantar fascia, and quadriceps tendon (Gerster et al., 1977). These periartricular deposits may be associated with inflammation but not all calcifc periarthritis is due to HA.

The results of microscopy of PP-containing cartilage have varied. The most characteristic finding is of rounded deposits of crystals in a granular matrix in the mid-zone, often in a line along the cartilage, resulting in a linear shadow on the x-ray picture (Bjelle, 1972; Reginato et al., 1974). Crystals have also been identified in perichondrocyte lacunae (McCarty et al., 1963; Schumacher, 1976) and in superficial cartilage (Žižnić and Sijaị, 1966; de Sèze et al., 1963). It is tempting to postulate that the deposits around mid-zone chondrocytes (each crystal is only 250-500 Å long) are the initial site of calcification and the superficial deposits the result of extensive loss of cartilage. Synovial deposits are also common in patients with PP chondrocalcinosis (Schumacher, 1976). These deposits are usually superficial and presumably come from the cartilage. Pachaz (1972), however, has found deposits of PP in the synovium in the absence of chondrocalcinosis, raising the possibility of active deposition outside the cartilage. These studies have not resolved the important question of whether cartilage changes or crystal deposits occur first. Nor have they determined if there are any differences between familial, metabolic, and sporadic cases.
Growth cartilage calcifies by the formation of needle-shaped microcrystals of HA in matrix vesicles adjacent to chondrocytes (Ali and Wisby, 1975). Similar appearances have been noted in osteoarthritic hyaline cartilage by Schumacher (1976), Ali (1977), and Doyle et al. (1978). Larger deposits of HA occur in the soft tissues of osteoarthritic joints (Collins, 1949; Fassbender, 1975). We do not know whether these are 'seeded' from bony or cartilagenous fragments; from the HA crystals in cartilage; or whether, as could be the case with pyrophosphates, the soft tissues are a second site of active calcification. The joints affected are those affected by primary generalised osteoarthritis (Kellgren and Moore, 1952). In HA calcific periarticular the affected joints are principally the shoulder and, to a lesser extent, the hip and others (Pinals and Short, 1965).

Thus both HA and PP are found in articular and periarticular tissues. Although the sites of deposition differ, morphological studies have not clarified the mechanism of formation of these deposits.

**Metabolic background to chondrocalcinosis**

Crystallisation occurs only when there is both a high enough concentration of metabolites and the physical conditions to initiate nucleation. Much is known of the metabolism of calcium, phosphorus, and inorganic pyrophosphate but very little of the nucleation of their salts.

Inorganic pyrophosphate is formed by many metabolic processes throughout the body, principally by the breakdown of ATP. Serum and urine levels are not altered in the forms of arthritis that have been studied, but synovial fluid levels are high in both PP deposition and osteoarthritis (Russell et al., 1971; Altman et al., 1973; Silcox and McCarty, 1973). The origin of synovial PP may be the chondrocytes, which have been shown to liberate PP from *in-vitro* cultures of cartilage slices (Howell et al., 1976). Nuki et al. (1978), however, have been unable to demonstrate this phenomenon using cultured mono-layers of chondrocytes.

Additional sources of joint PP may include other cells, subchondral bone, and the crystals themselves. Breakdown of inorganic PP is a major source of simple phosphate radicals, a process accelerated by specific pyrophosphatases and by the alkaline phosphatase that is found in cartilage (Ali, 1977). Calcium metabolism is in part controlled by parathormone. McCarty and O'Duffy (1976) have reported high levels of parathormone in both PP arthropathy and osteoarthritis. Local levels of free calcium in cartilage may depend on proteoglycan binding, and loss of proteoglycans may predispose to calcification (Benderly and Maroudas, 1975). This argues in favor of chondrocalcinosis being secondary to cartilage damage. Proteoglycans are also a possible site of crystal nucleation, but the most likely site of formation of HA is the chondrocyte matrix vesicles (Ali et al., 1970; Ali, 1977).

The interrelationships between PP, DCPP, and HA seem complex. Pyrophosphate inhibits the formation of apatite and apatite formation is aided by alkaline phosphatase, itself a powerful pyrophosphatase (Fleisch et al., 1966). DCPD may be intermediary in the formation of HA.

The appearance of different salts in the same clinical situation and the coexistence of different salts in the same tissue is hard to explain. A simplified outline of some possible metabolic interrelationships, based on the work of Howell (1978), is shown in Fig. 3.

Most cases of PP deposition are idiopathic, but familial cases have been reported. A few may be secondary to other metabolic disease. The only unequivocal metabolic situation predisposing to apatite deposition is chronic renal failure (Canner and Decker, 1964; Lain et al., 1977). There is a long list of possible metabolic causes, but they are difficult...
New knowledge of chondrocalcinosis

Fig. 3 Diagrammatic outline of some metabolic pathways participating in calcium crystal formation in cartilage.

to prove since only one controlled study has been made (McCarty et al., 1974). Investigation of the secondary causes of crystal deposition should aid understanding of the phenomenon. For example, Hamilton et al. (1968) have defined various special features of the disease when it is associated with haemachromatosis, an association which may be due to local deposits of iron aiding nucleation of PP crystals. Similarly, the association with hypomagnesaemia may be because magnesium ions normally bind inorganic PP. Hypophosphatasia causes PP deposits because of low levels of alkaline phosphatase (Eade and Swannell, 1977). The other associations of PP deposition have been reviewed by Hamilton (1976).

New aspects of features associated with chondrocalcinosis: radiological features

Wolke (1935) reported that 0.19% of a population surveyed radiologically showed evidence of chondrocalcinosis. Subsequent radiological surveys suggested that the incidence of chondrocalcinosis is nearer 5% (McCarty 1977). Recently Ellman and Levin (1975) studied an elderly Jewish population and found that 27.6% had chondrocalcinosis. These discrepancies are partly due to the different ages of the populations studied; chondrocalcinosis is more common in the elderly (Menin et al., 1977). Genant (1976) described the conditions necessary for good radiological visualisation. Gerster et al. (1977) documented the radiological signs of periarticular tendon calcification in patients with chondrocalcinosis, and Resnick et al. (1977) described the characteristic radiological features of chronic PP arthropathy that distinguish it from osteoarthritis.

Chondrocalcinosis usually results in a linear shadow in x-ray pictures. However, ‘spotty’ or rounded deposits are also seen, particularly in osteoarthritis where they are often described as ‘loose bodies’. Analysis of the type of mineral in the tissues and synovial fluid of patients with linear or spotty deposits has shown that most linear deposits are associated with PP deposition and most spotty deposits with HA (Table) (Dieppe, 1978). However, the relationship is not perfect, re-emphasising that the nature of cartilage deposits should not be interpreted from radiographs alone.

Crystals in synovial fluid

PP and HA crystals are unlikely to precipitate directly in synovial fluid, but DCPD crystals may form in the fluid after its removal from the joints (Dieppe et al., 1978). Crystals deposited in cartilage may or may not appear in the synovial fluid. Bennett et al. (1976) postulated that they appear only in the presence of some ‘factor’ that increases solubility, decreasing the size of the deposit and resulting in ‘crystal shedding’ into the joint space. For these reasons, examination of synovial fluid cannot be regarded as a satisfactory method for detecting chondrocalcinosis.

Furthermore, accurate identification of crystals in synovial fluid is difficult. To be identified by light microscopy they must be at least 0.5 μm long. The initial deposits of both PP and HA are much smaller. HA can be identified by analytical electron microscopy. I have mentioned the limitations of this technique but it has led to clear descriptions of HA-induced crystal synovitis (Dieppe et al., 1976; Schumacher et al., 1977) (Fig. 5). The lack of correlation between the numbers of crystals seen in synovial fluids and the clinical features of the arthritis, described by McCarty (1974a), has been a feature of our studies and remains unexplained.

Table Relationship between radiological signs and type of crystal identified in synovial fluid in chronic arthritis

<table>
<thead>
<tr>
<th>Radiological signs</th>
<th>Crystals identified</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Pyrophosphate</td>
</tr>
<tr>
<td>Linear calcification</td>
<td>4</td>
</tr>
<tr>
<td>Spotty calcification</td>
<td>1</td>
</tr>
<tr>
<td>None</td>
<td>2</td>
</tr>
</tbody>
</table>

Arthritis

McCarty (1974b) described four important clinical associations of PP deposition: ‘pseudogout’, ‘pseudooesteoarthritis’, ‘pseudorheumatoid arthritis’, and
'pseudoneurotrophic joints'. The first two are the most common. Other conditions described include spinal stiffness (Reginato et al., 1970), haemarthrosis (Phelip et al., 1976), acute spinal pain, and polynylalgia rheumatica (Storey and Huskisson, 1976). PP crystals provoke inflammation (see below), and the synovitis of pseudogout is almost certainly caused in this way (Schumacher, 1976).

The association between the presence of the crystals and the other forms of arthritis is obscure. Chondrocalcinosis is common but it is difficult to be certain of the significance of associations with common conditions. The association of chronic and destructive arthritis (Richards and Hamilton, 1974) with chondrocalcinosis is common but is unexplained. Žitnian and Silaj (1976) have evidence that in familial cases chondrocalcinosis appears before chronic arthritis. But crystal deposition could be an epiphenomenon resulting from the same metabolic changes that cause the cartilage damage. The few reports of DCPD deposition suggest an association with a chronic destructive arthritis similar to chronic PP arthropathy (Moskowitz et al., 1971; Faure et al., 1977; Utsinger, 1977).

HA crystals have been associated with four forms of arthritis—acute calcific periarthritis (Pinals and Short, 1966), osteoarthritis (Dieppe et al., 1976; Huskisson et al., 1978), synovitis in renal failure (Lain et al., 1977), and an acute arthritis (Schumacher et al., 1977). A causal relationship between the acute syndromes and the crystals seems reasonable in view of their inflammatory potential. Their role in osteoarthritis is not clear. Huskisson et al. (1978) and Ali (1978) have evidence of a link between HA deposition and osteoarthritis and, although probably a secondary phenomenon, it may explain some of the inflammatory features of this disease (Dieppe et al., 1978).

**Crystal-induced inflammation**

After PP crystals were identified experiments showed that they could cause acute inflammation (McCarty et al., 1966). HA crystals are also phlogistic (Dieppe et al., 1976; Denko and Whitehouse, 1976; Schumacher et al., 1976). PP crystals react with

---

Fig. 4  *Transmission electron micrograph of phagocytic cell from human osteoarthritic synovial fluid. Aggregates of hydroxyapatite crystals are seen within a phagosome.*
New knowledge of chondrocalcinosis

leucocytes, are phagocytosed (Tse and Phelps, 1970), have membranolytic activity (Wallingford and McCarty, 1971), and cause release of a chemotactic factor (Spilberg et al., 1975). These responses tend to be quantitatively less than with urate. The reaction is complement-independent and is mediated in a similar way to other forms of acute inflammation (Willoughby, 1975). Less is known about HA crystals. They are phagocytosed (Fig. 4) (Maurer and Schumacher, 1977) and can cause chronic as well as acute inflammation (Dunn et al., 1978).

Important determinants of the phlogistic properties of crystals include surface charge, the ability to bind protein (especially IgG), and crystal size—smaller crystals are more inflammatory than larger (Dunn et al., 1978). Scanning electron microscopy has revealed a wide variety in size and shape of crystal deposits and this may have a bearing on clinical sequelae (Fig. 5). There have been recent reviews of some aspects of crystal-induced inflammation (Schumacher, 1977; Dunn et al., 1978; Allison, 1978). There is now considerable understanding of acute inflammation (and thus ‘pseudogout’ or acute calcific periarthritis) but little knowledge of how, if at all, crystals contribute to chronic disease.

Conclusions

Calcium pyrophosphate was thought of as the salt of chondrocalcinosis, but clearly many different calcium phosphates may be deposited in articular cartilage. Some cases are familial and a few secondary to metabolic disease, but in most there is no obvious cause for the calcification. Recent work on the pathology and metabolism of cartilage has drawn attention to its activity and the delicate balance between the activators and inhibitors of calcification.
Chondrocalcinosis may be accompanied by three clinical phenomena—radiological changes, crystals in the synovial fluid, and arthritis. The application of new analytical techniques to the study of synovial fluid has enabled hydroxyapatite and other crystals to be identified and their presence correlated with radiological features and symptoms. Both hydroxyapatite and pyrophosphate crystals are inflammatory and acute synovitis can result from their presence in joints. Chondrocalcinosis, however, is more often associated with chronic joint disease, and in these cases calcification may be the clue to an underlying metabolic defect responsible for some forms of 'degenerative' arthritis.

References

New knowledge of chondrocalcinosis


Wolke, K. (1935). Über Meniskus-und Gelenkkno-


New knowledge of chondrocalcinosis

Paul Dieppe

doi: 10.1136/jcp.31.Suppl_12.214

Updated information and services can be found at:
http://jcp.bmj.com/content/31/Suppl_12/214.citation

Email alerting service

*These include:*
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/